This article delves into the critical need for reform in public spending...
Fundamentals for Global Health Limited
Last Updated:
2025-10-16 19:37
Overall Fundamental outlook
Business Operations:
Sector: Healthcare Industry: Medical Care Facilities
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in New Delhi, India.
Revenue projections:
Revenue projections for MEDANTA Investors may react cautiously to news that MEDANTA's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.
Financial Ratios:
currentRatio
0.00000
forwardPE
46.37328
debtToEquity
21.18800
earningsGrowth
0.49200
revenueGrowth
0.19700
grossMargins
0.53662
operatingMargins
0.17644
trailingEps
19.87000
forwardEps
23.41000
MEDANTA's low Debt-to-Equity ratio means the company is not over-leveraged, highlighting its conservative use of debt. This suggests reduced financial risk and a stable balance sheet, making MEDANTA a financially resilient company with lower exposure to debt-related pressures. MEDANTA's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods. MEDANTA's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting MEDANTA to generate stronger earnings compared to the previous financial year.
Price projections:
Price projections for MEDANTA Global Health Limited's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.
Recommendation changes over time:
Recommendations trend for MEDANTA
Analysts' buy bias toward MEDANTA suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, MEDANTA is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
An in-depth look at the UK’s Q2 2025 GDP release by ONS,...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.